Alessandra Ferrajoli, MD

Alessandra Ferrajoli, MD, discusses the importance of shared decision-making when considering the use of BTK inhibitors in hematologic malignancies.

Alessandra Ferrajoli, MD, discusses the rationale for, and findings from, a cumulative review of hypertension in patients with chronic lymphocytic leukemia and other hematologic malignancies who received acalabrutinib.

Alessandra Ferrajoli, MD, discusses the benefits and limitations of utilizing fixed-duration therapy with monoclonal antibodies in the frontline setting for patients with chronic lymphocytic leukemia.

Alessandra Ferrajoli, MD, a professor of Medicine in the Department of Leukemia at The University of Texas MD Anderson Cancer Center, discusses the challenges that still remain in patients with chronic lymphocytic leukemia.

Alessandra Ferrajoli, MD, associate professor, Department of Leukemia, Division of Cancer Medicine, the University of Texas MD Anderson Cancer Center, discusses treatment options for elderly patients with chronic lymphocytic leukemia.

Alessandra Ferrajoli, MD, from The University of Texas MD Anderson Cancer Center, discusses managing chronic lymphocytic leukemia (CLL) in elderly patients.

Alessandra Ferrajoli, MD, associate professor, Department of Leukemia, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, discusses individualizing the treatment of chronic lymphocytic leukemia (CLL).

Alessandra Ferrajoli, MD, discusses the recent approval of ibrutinib for patients with chronic lymphocytic leukemia (CLL) who have received at least one previous therapy.